<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04470063</url>
  </required_header>
  <id_info>
    <org_study_id>DDO-3055-104</org_study_id>
    <nct_id>NCT04470063</nct_id>
  </id_info>
  <brief_title>Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Patients With Anemia of Non-dialysis Chronic Kidney Diseases.</brief_title>
  <official_title>A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multi-dose DDO-3055 Tablets in Patients With Anemia of Non-dialysis Chronic Kidney Diseases—Randomized, Double-blind, Dose Escalation, Placebo Controlled Phase I Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and
      pharmacodynamics of multi-dose DDO-3055 tablets in patients with anemia of non-dialysis
      chronic kidney diseases.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2020</start_date>
  <completion_date type="Anticipated">March 4, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence and severity of adverse events to assess safety and tolerability.</measure>
    <time_frame>up to 37 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Anemia Associated Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DDO-3055 tablets</intervention_name>
    <description>Multi-dose for DDO-3055 tablets</description>
    <arm_group_label>group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
    <arm_group_label>group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Multi-dose for Placebo</description>
    <arm_group_label>group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
    <arm_group_label>group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with CKD anemia aged 18-70 years who were not on dialysis and were not
             expected to undergo dialysis during the study period, regardless of gender;

          -  Male weight≥50kg, female weight≥45kg, and 19kg/m2≤BMI&lt;28kg/m2;

          -  Signed informed consent.

        Exclusion Criteria:

          -  Allergic constitution, suspected to be allergic to the study drug or any component in
             the study drug;

          -  Patients with acute coronary syndrome, stroke, thromboembolism (such as deep vein
             thrombosis or pulmonary embolism) or a history of seizures within 6 months before
             screening;

          -  Patients with uncontroll ed hypertension;

          -  New York Heart Association grade III or IV congestive heart failure at the time of
             screening;

          -  ALT,AST or total bilirubin exceeds 1.5 times the upper limit of normal value (ULN)
             during the screening period;

          -  Suffer from anemia other than CKD.

          -  Patients with a history of chronic liver disease;

          -  Patients with active bleeding or known coagulopathy;

          -  Patients who have any previous organ transplant or plan to perform organ transplant;

          -  Intravenous iron supplementation within 1 month before screening;

          -  Used erythropoiesis stimulator (ESAs), hypoxia-inducible factor-prolyl hydroxylase
             inhibitor (HIF-PHI), androgen, blood transfusion therapy within 3 months before
             screening;

          -  Hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), syphilis antibody,
             and human immunodeficiency virus (HIV) antibody were positive;

          -  Patients with blood loss ≥400mL within 3 months before screening;

          -  Subjects who have taken other clinical trial drugs or are expected to have a legacy
             effect of the trial treatment;

          -  Participants who are unwilling to take contraception or male subjects who cannot
             guarantee not to donate sperm during the trial and within 30 days after the last dose;
             female subjects with fertility who did not use contraception for at least 14 days
             before dosing;or male and female subjects who did not agree to use physical
             contraception during the trial;

          -  Patients who had a positive blood pregnancy test and were breastfeeding at the time of
             screening;

          -  According to the study physician's judgment, there may be any other anemia factors
             that may exist, any possibility to increase the risk of the study, affect the
             subject's compliance with the protocol, or affect the physical or psychological
             disease or condition of the subject to complete the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiong Jun ye</last_name>
    <phone>+86 18036618716</phone>
    <email>xiongjunye@hrglobe.cn</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>July 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>July 11, 2020</last_update_submitted>
  <last_update_submitted_qc>July 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

